Profile data is unavailable for this security.
About the company
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
- Revenue in NOK (TTM)537.59m
- Net income in NOK2.12m
- Incorporated1995
- Employees101.00
- LocationPhotocure ASAHoffsveien 4OSLO 0275NorwayNOR
- Phone+47 22062210
- Fax+47 22062218
- Websitehttps://photocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biohit Oyj | 177.00m | 30.44m | 402.34m | 46.00 | 16.43 | 2.98 | 10.50 | 2.27 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 8.05m | -25.39m | 439.01m | 13.00 | -- | 5.11 | -- | 54.55 | -1.02 | -1.02 | 0.3142 | 3.15 | 0.0862 | -- | 10.59 | 581,461.60 | -27.20 | -8.36 | -29.49 | -9.10 | 82.54 | 121.50 | -315.49 | -53.37 | -- | -1,153.67 | 0.00 | -- | -60.95 | 55.82 | -1,182.15 | -- | 9.13 | -- |
| Enzymatica AB (publ) | 56.14m | -57.64m | 444.47m | 21.00 | -- | 3.08 | -- | 7.92 | -0.2257 | -0.2257 | 0.2198 | 0.559 | 0.292 | 1.26 | 4.54 | 2,510,953.00 | -29.98 | -29.10 | -31.26 | -34.48 | 63.76 | 63.82 | -102.68 | -73.32 | -- | -- | 0.0095 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
| Moberg Pharma AB (publ) | 13.30m | -274.44m | 475.54m | 6.00 | -- | 0.6367 | -- | 35.74 | -5.52 | -5.52 | 0.2672 | 14.40 | 0.0153 | 0.9991 | 1.87 | 1,388,556.00 | -31.46 | -- | -32.04 | -- | 52.35 | -- | -2,062.80 | -- | 15.81 | -- | 0.0044 | -- | -- | -- | -1,109.46 | -- | -- | -- |
| Navamedic ASA | 539.42m | -39.43m | 525.19m | 45.00 | -- | 2.50 | -- | 0.9736 | -2.21 | -2.21 | 27.98 | 8.74 | 0.883 | 3.27 | 6.40 | 12,843,290.00 | -6.45 | -0.3087 | -8.75 | -0.4895 | 37.32 | 39.37 | -7.31 | -0.2916 | 0.7697 | 0.192 | 0.5978 | -- | 3.80 | 23.00 | 59.92 | -- | 35.76 | -- |
| Dicot Pharma AB | 134.14k | -89.42m | 682.38m | 4.00 | -- | 7.10 | -- | 5,087.15 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -84.88m | 781.64m | 10.00 | -- | 6.11 | -- | -- | -5.92 | -5.92 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.19 | -22.82 | -48.56 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 51.55m | -188.48m | 858.09m | 19.00 | -- | 1.91 | -- | 16.65 | -3.80 | -3.80 | 1.04 | 9.07 | 0.0777 | -- | 15.47 | 3,724,539.00 | -28.43 | -- | -32.01 | -- | -- | -- | -365.65 | -- | -- | -- | 0.0197 | -- | -23.14 | -- | 21.89 | -- | -- | -- |
| Vistin Pharma ASA | 454.84m | 78.06m | 940.11m | 77.00 | 12.04 | 3.01 | 9.44 | 2.07 | 1.76 | 1.76 | 10.26 | 7.05 | 1.12 | 1.87 | 6.20 | -- | 19.20 | 1.65 | 23.64 | 1.99 | 66.40 | 62.28 | 17.16 | 1.88 | 1.16 | -- | 0.063 | -- | -1.45 | 13.56 | 37.62 | -1.03 | 17.32 | -- |
| Orexo AB | 411.35m | -214.09m | 1.00bn | 72.00 | -- | 1.91 | -- | 2.43 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -113.14m | 1.06bn | 8.00 | -- | 5.10 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
| Arcticzymes Technologies ASA | 103.07m | 7.66m | 1.14bn | 55.00 | 152.28 | 3.45 | 69.01 | 11.05 | 0.1464 | 0.1464 | 1.97 | 6.47 | 0.2967 | 0.295 | 1.91 | 1,874,073.00 | 2.20 | 13.28 | 2.32 | 14.39 | 95.42 | 96.20 | 7.43 | 31.41 | 15.45 | -- | 0.0184 | 0.00 | -12.26 | 18.22 | -56.40 | -- | 53.98 | -- |
| Photocure ASA | 537.59m | 2.12m | 1.71bn | 101.00 | 779.12 | 3.44 | 54.35 | 3.18 | 0.0809 | 0.0809 | 20.00 | 18.29 | 0.7587 | 1.15 | 8.11 | 5,322,683.00 | 0.2993 | -3.65 | 0.3389 | -4.19 | 92.83 | 94.00 | 0.3945 | -6.26 | 3.87 | -- | 0.00 | -- | 4.94 | 13.29 | -441.16 | -- | 65.53 | -- |
Data as of Feb 16 2026. Currency figures normalised to Photocure ASA's reporting currency: Norwegian Krone NOK
37.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Briarwood Chase Management LLCas of 28 Feb 2025 | 5.47m | 20.17% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 2025 | 2.00m | 7.37% |
| MP Pensjon PKas of 31 Dec 2024 | 688.42k | 2.54% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 586.15k | 2.16% |
| Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025 | 450.00k | 1.66% |
| DNB Asset Management ASas of 28 Nov 2025 | 227.50k | 0.84% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 207.16k | 0.76% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 206.85k | 0.76% |
| KLP Kapitalforvaltning ASas of 31 Dec 2025 | 205.03k | 0.76% |
| Equinor Asset Management ASAas of 30 Jun 2025 | 98.57k | 0.36% |
More ▼
Data from 30 Jun 2025 - 26 Jan 2026Source: FactSet Research Systems Inc.
